Octapharma AG has entered into a marketing and commercialization agreement with Pfizer for human prothrombin complex concentrate (PCC), an investigational agent under FDA review for the urgent reversal of Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients who require urgent surgery or invasive procedures. Octapharma has exclusive rights to commercialize the product globally, except the U.S., where Pfizer will be responsible for marketing and commercialization.   Octapharma’s PC...